Research Article
Serum Autoantibodies against STIP1 as a Potential Biomarker in the Diagnosis of Esophageal Squamous Cell Carcinoma
Table 5
Relationship between positive rate of the STIP1 autoantibodies and clinical data in ESCC patients from the validation cohort.
| | N | Positive (%, 95% CI) | P |
| Age | ≥58 | 32 | 13 (40.6, 24.2–59.2) | 0.916 | <58 | 28 | 11 (39.3, 22.2–59.3) | | Gender | Male | 38 | 14 (36.8, 22.3–54.0) | 0.512 | Female | 22 | 10 (45.5, 25.1–67.3) | | Smoke | Yes | 36 | 13 (36.1, 21.3–53.8) | 0.451 | No | 24 | 11 (45.8, 26.2–66.8) | | Site of tumor | Upper thorax | 10 | 3 (30.0, 8.1–64.6) | 0.724 | Middle thorax + low thorax | 50 | 21 (42.0, 28.5–56.7) | | Size of tumor | <5 cm | 24 | 9 (37.5, 19.6–59.2) | 0.747 | ≥5 cm | 36 | 15 (41.7, 26.0–59.1) | | Depth of tumor invasion | T1 + T2 | 21 | 9 (42.9, 22.6–65.6) | 0.800 | T3 + T4 | 38 | 15 (39.5, 24.5–56.5) | | Regional lymph nodes | N0 | 31 | 12 (38.7, 22.4–57.7) | 0.833 | N1 + N2 + N3 | 29 | 12 (41.4, 24.1–60.9) | | Histological grade | G1 | 17 | 6 (35.3, 15.3–61.4) | 0.659 | G2 | 36 | 16 (44.4, 28.3–61.7) | | G3 | 7 | 2 (28.6, 5.1–69.7) | | TNM stage | Early stage (0 + I + IIA) | 13 | 5 (38.5, 15.1–67.7) | 0.898 | Advanced stage (IIB + III + IV) | 47 | 19 (40.4, 26.7–55.7) | |
|
|
ESCC: esophageal squamous cell carcinoma; CI: exact confidence interval. Statistical significance was determined using the chi-square test.
|